Investigating the Link Between Type 2 Immunity and NAFLD in Human Obesity- AIM 2


About this study

This study is being done to better understand the relationship between inflammation in your AT, abnormal deposition of fat around your liver and how this affects its appearance and function and ultimately insulin resistance.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Undergoing RYGBS.
  • Confirmed AUROC F>2 liver fibrosis.
  • Age 30-70 years old.
  • BMI greater than 40 kg/m2.
  • Negative pregnancy test (female only).
  • Lab Values: Hematocrit≥ 35 vol%.
  • Lab Values: INR < 1.3.
  • Lab Values: Normal TSH.

Exclusion Criteria:

  • Autoimmune diseases.
  • Hepatitis B or C positive.
  • Heavy alcohol use.
  • Active smoking history.
  • Active cancer history.
  • History of asthma.
  • History of COPD.
  • Taking Plavix or Coumadin.
  • Blood donation within past 2 months.
  • Glucocorticoid therapy.
  • Taking antihistamine on regular basis.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Elena Anna De Filippis, M.D., Ph.D.

Open for enrollment

Contact information:

Rachel Kendrick

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer